NVO — All updates

Novo Nordisk informed investors that it will increase its revenue at a medium single-digit rate through 2030. It also stated that it will increase the number of patients it serves to more than 60 million, up from about 46.5 million currently.

Despite these strong expectations, investors were not impressed with Novo Nordisk's performance. The stock has fallen by more than 25% since the beginning of 2026. So, does all this make Novo a buying opportunity when its price drops?

Now let's talk about Novo, formerly known as Novo Nordisk. The company's shares are under pressure this morning. The market appears to be dissatisfied with the plan revealed by Novo regarding its strategy for the next phase.

It is clear that they saw a large demand for their weight loss drug, at least in its early stages. But now, competition has entered this field and captured part of their market share.

All right. And last but not least, we look at Novo Nordisk. I saw a downgrade and a price target below where we are now.